Hypereosinophilic Syndrome of Undetermined Significance – Difficulties in Clinical and Therapeutic Approach

1. Gotlib J. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification and management. Annual Clinical Update in Hematological Malignancies. Am J Hematol. 89; 326-337, 2014.10.1002/ajh.2366424577808Search in Google Scholar

2. Simon HU, Rothenberg ME, Bochner BS, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol. 2010;126(1):45-4910.1016/j.jaci.2010.03.042340002420639008Search in Google Scholar

3. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975; 54: 1-27.10.1097/00005792-197501000-000011090795Open DOISearch in Google Scholar

4. Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis : current concepts in diagnosis and treatment. Ann Hematol 2002, 81: 677-6901248336310.1007/s00277-002-0575-z12483363Search in Google Scholar

5. Valent P, Akin C and Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts, BLOOD, 16 March 2017, Volume 129, Number 1110.1182/blood-2016-09-731893535645428031180Search in Google Scholar

6. Valent P, Klion AD, Horny HP et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012; 130: 607-612.10.1016/j.jaci.2012.02.019409181022460074Search in Google Scholar

7. Klion AD, Noel P, Akin C et al. Nutman Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003, Vo.101, Number 1210.1182/blood-2003-01-000612676775Search in Google Scholar

8. Curtis C, Ogbogu P. Hypereosinophilic Syndrome. Clinic Rev Allerg Immunol. 2015,10.1007/s12016-015-8506-726475367Search in Google Scholar

9. Klion AD, Bochner BS, Gleich GJ et al. The Hypereosinophilic Syndromes Working Group. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol.2006; 117: 1292-1302.10.1016/j.jaci.2006.02.04216750989Search in Google Scholar

10. Cools J, DeAngelo DJ, Gotlib J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348; 1201-1214.10.1056/NEJMoa02521712660384Search in Google Scholar